全文获取类型
收费全文 | 2978篇 |
免费 | 212篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 198篇 |
妇产科学 | 136篇 |
基础医学 | 493篇 |
口腔科学 | 31篇 |
临床医学 | 213篇 |
内科学 | 497篇 |
皮肤病学 | 48篇 |
神经病学 | 184篇 |
特种医学 | 37篇 |
外科学 | 486篇 |
综合类 | 118篇 |
预防医学 | 169篇 |
眼科学 | 43篇 |
药学 | 213篇 |
中国医学 | 13篇 |
肿瘤学 | 303篇 |
出版年
2023年 | 24篇 |
2022年 | 22篇 |
2021年 | 97篇 |
2020年 | 56篇 |
2019年 | 84篇 |
2018年 | 86篇 |
2017年 | 63篇 |
2016年 | 73篇 |
2015年 | 70篇 |
2014年 | 105篇 |
2013年 | 133篇 |
2012年 | 210篇 |
2011年 | 231篇 |
2010年 | 122篇 |
2009年 | 121篇 |
2008年 | 187篇 |
2007年 | 166篇 |
2006年 | 125篇 |
2005年 | 127篇 |
2004年 | 102篇 |
2003年 | 99篇 |
2002年 | 95篇 |
2001年 | 54篇 |
2000年 | 26篇 |
1999年 | 42篇 |
1998年 | 13篇 |
1997年 | 14篇 |
1996年 | 14篇 |
1995年 | 18篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1992年 | 27篇 |
1991年 | 36篇 |
1990年 | 26篇 |
1989年 | 32篇 |
1988年 | 26篇 |
1987年 | 24篇 |
1986年 | 36篇 |
1985年 | 18篇 |
1984年 | 21篇 |
1983年 | 16篇 |
1981年 | 10篇 |
1979年 | 17篇 |
1975年 | 15篇 |
1974年 | 18篇 |
1973年 | 12篇 |
1972年 | 10篇 |
1971年 | 13篇 |
1970年 | 16篇 |
1966年 | 10篇 |
排序方式: 共有3198条查询结果,搜索用时 31 毫秒
1.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
2.
Junyu Chen Michelle Hendriks Alexandros Chatzis Saravana K Ramasamy Anjali P Kusumbe 《Journal of bone and mineral research》2020,35(11):2103-2120
Bone vasculature and bone marrow vascular niches supply oxygen, nutrients, and secrete angiocrine factors required for the survival, maintenance, and self-renewal of stem and progenitor cells. In the skeletal system, vasculature creates nurturing niches for bone and blood-forming stem cells. Blood vessels regulate hematopoiesis and drive bone formation during development, repair, and regeneration. Dysfunctional vascular niches induce skeletal aging, bone diseases, and hematological disorders. Recent cellular and molecular characterization of the bone marrow microenvironment has provided unprecedented insights into the complexity, heterogeneity, and functions of the bone vasculature and vascular niches. The bone vasculature is composed of distinct vessel subtypes that differentially regulate osteogenesis, hematopoiesis, and disease conditions in bones. Further, bone marrow vascular niches supporting stem cells are often complex microenvironments involving multiple different cell populations and vessel subtypes. This review provides an overview of the emerging vascular cell heterogeneity in bone and the new roles of the bone vasculature and associated vascular niches in health and disease. © 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). 相似文献
3.
Anjali Hirani Aditya Grover Yong W. Lee Yashwant Pathak 《Pharmaceutical development and technology》2016,21(1):61-67
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the US affecting millions yearly. It is characterized by intraocular neovascularization, inflammation and retinal damage which can be ameliorated through intraocular injections of glucocorticoids. However, the complications that arise from repetitive injections as well as the difficulty posed by targeting the posterior segment of the eye make this interesting territory for the development of novel drug delivery systems (DDS). In the present study, we described the development of a DDS composed of triamcinolone acetonide-encapsulated PEGylated PLGA nanoparticles (NP) incorporated into PLGA–PEG–PLGA thermoreversible gel and its use against VEGF expression characteristic of AMD. We found that the NP with mean size of 208?±?1.0?nm showed uniform size distribution and exhibited sustained release of the drug. We also demonstrated that the polymer can be injected as a solution and transition to a gel phase based on the biological temperature of the eye. Additionally, the proposed DDS was non-cytotoxic to ARPE-19 cells and significantly reduced VEGF expression by 43.5?±?3.9% as compared to a 1.53?±?11.1% reduction with triamcinolone. These results suggest the proposed DDS will contribute to the development of novel therapeutic strategies for AMD. 相似文献
4.
5.
Sathiyavelavan Gopalan Jagadesh Chandra Bose S. Periasamy 《The Indian journal of surgery》2015,77(3):232-236
The aim of this study is to review the literature to find out the exact etiology of anastomotic cancers of colon post resection and differentiate them between a recurrence, second primary, and metastatic disease (local manifestation of systemic disease). Web-based literature search was done, and datas collected. We searched PubMed for papers using the keywords colon cancer recurrence, anastomotic recurrence, and recurrent colon carcinoma. We also searched for systematic review in the same topic. In addition, we used our personal referrence archive. Anastomotic recurrences of colon are postulated to arise due to inadequate margins, tumor implantation by exfoliated cells, altered biological properties of bowel anastomosis, and missed synchronous lesions. Some tumors are unique with repeated recurrence after repeated resection. Duration after primary surgery plays a major role in differentiating recurrent and second primary lesions. Repeated recurrences after repeated resections have to be considered a manifestation of systemic disease or metastatic disease due to the virulence of the disease. A detailed analysis and study of patients with colonic anastomotic lesion are required to differentiate it between a recurrent, a second primary lesion, and a metastatic disease (local manifestation of a systemic disease). The nomenclature is significant to study the survival of these patients, as a second primary lesion will have different survival compared to that of recurrent lesions. 相似文献
6.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75
7.
8.
Arunaloke Chakrabarti Prashant Sood Shivaprakash M. Rudramurthy Sharon Chen Joseph Jillwin Ranganathan Iyer Ajanta Sharma Belgode Narasimha Harish Indranil Roy Anupma J. Kindo Deepinder Chhina Jayanthi Savio Deepak Mendiratta Malini R. Capoor Shukla Das Anita Arora Jagdish Chander Immaculata Xess Appalaraju Boppe Ujjwayini Ray Ratna Rao Vandana Kalwaje Eshwara Sangeeta Joshi Atul Patel Raman Sardana Anjali Shetty Umabala Pamidimukkala for the SIHAM Candidemia Network 《Mycoses》2020,63(11):1149-1163
9.
Warren Fiskus Christopher P. Mill Behnam Nabet Dimuthu Perera Christine Birdwell Taghi Manshouri Bernardo Lara Tapan M. Kadia Courtney DiNardo Koichi Takahashi Naval Daver Prithviraj Bose Lucia Masarova Naveen Pemmaraju Steven Kornblau Gautam Borthakur Guillermo Montalban-Bravo Guillermo Garcia Manero Sunil Sharma Matthew Stubbs Xiaoping Su Michael R. Green Cristian Coarfa Srdan Verstovsek Joseph D. Khoury Christopher R. Vakoc Kapil N. Bhalla 《Blood cancer journal》2021,11(5)
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers, altering gene-expressions and inducing differentiation and lethality in AML and (MPN) sAML cells. A protein domain-focused CRISPR screen in LSD1 (KDM1A) inhibitor (i) treated AML cells, identified BRD4, MOZ, HDAC3 and DOT1L among the codependencies. Our findings demonstrate that co-targeting LSD1 and one of these co-dependencies exerted synergistic in vitro lethality in AML and post-MPN sAML cells. Co-treatment with LSD1i and the JAKi ruxolitinib was also synergistically lethal against post-MPN sAML cells. LSD1i pre-treatment induced GFI1, PU.1 and CEBPα but depleted c-Myc, overcoming nongenetic resistance to ruxolitinib, or to BETi in post-MPN sAML cells. Co-treatment with LSD1i and BETi or ruxolitinib exerted superior in vivo efficacy against post-MPN sAML cells. These findings highlight LSD1i-based combinations that merit testing for clinical efficacy, especially to overcome nongenetic therapy-resistance in AML and post-MPN sAML.Subject terms: Acute myeloid leukaemia, Targeted therapies 相似文献
10.